Lilly's Trulicity beats Sanofi's Lantus in study of type 2 diabetics

|By:, SA News Editor

Data presented today at the American Diabetes Association Scientific Sessions in Boston, showed Eli Lilly's (LLY +0.2%) Trulicity (dulaglutide) injection provided superior hemoglobin A1c reduction compared to Sanofi's (NYSE:SNY) Lantus (insulin glargine [rDNA origin] injection) in type 2 diabetics.

After 26 weeks, both doses of Trulicity were more effective in reducing A1c levels below 7% than Lantus. The reductions in A1c from baseline for Trulicity 0.75 mg, Trulicity 1.5 mg and Lantus were -1.32%, -1.7% and -1.15%, respectively.

Patients receiving Trulicity also lost weight. Those receiving 0.75 mg and 1.5 mg lost an average of 0.88 kg and 1.51 kg, respectively, while those receiving Lantus gained an average of 0.96 kg.

Trulicity was approved in the U.S. in September 2014 and in Europe in two months later.

Subscribe for full text news in your inbox